Milestone® Biotechnologies announced that it has raised over CNY 100 million in a round of funding led by new investor, Weifang Zhongke Haichuang Equity Investment Partnership Enterprise (Limited Partnership), a fund managed by Haichuang Tiancheng (Guangzhou) Equity Investment Fund Management Co., Ltd., an investment arm on August 22, 2023. The transaction also included participation from new investors, Jiangsu Addor Equity Investment Fund Management Co., Ltd., GL Ventures, Shanghai Titan Scientific Co., Ltd. and Jiaxing Tongyu Private Equity Fund Management Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.27 CNY | +1.91% | -3.18% | -39.01% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.01% | 462M | |
+17.80% | 66.73B | |
+2.92% | 49.79B | |
+19.98% | 42.5B | |
+20.88% | 26.45B | |
+12.04% | 19.66B | |
+1.27% | 17.18B | |
-22.98% | 15.82B | |
+2.77% | 15.56B | |
-9.25% | 15.41B |
- Stock Market
- Equities
- 688133 Stock
- News Shanghai Titan Scientific Co., Ltd.
- Milestone® Biotechnologies announced that it has received CNY 100 million in funding from Haichuang Tiancheng Equity Investment Fund Management Co., Ltd., Jiangsu Addor Equity Investment Fund Management Co., Ltd., GL Ventures, Shanghai Titan Scientific Co., Ltd., Jiaxing Tongyu Private Equity Fund Management Co., Ltd.